Nina M. Muñoz Kiem lab May 18th, 2009

Slides:



Advertisements
Similar presentations
Supplementary Fig.1: oligonucleotide primer sequences.
Advertisements

Figure S1. Sequence alignment of yeast and horse cyt-c (Identity~60%), green highly conserved residues. There are 40 amino acid differences in the primary.
I-SceI-mediated Genome Editing in the Canine Model Kiem lab Applications Meeting Feb 23, 2009.
NGEC Applications Meeting Mike Certo Scharenberg Lab.
Immunotherapy with CD19 CAR redirected T-cells for high risk, relapsed paediatric CD19+ acute lymphoblastic leukaemia (ALL) and other haematological malignancies.
Volume 19, Issue 1, Pages (January 2011)
Volume 16, Issue 3, Pages (March 2008)
Sequence – 5’ to 3’ Tm ˚C Genome Position HV68 TMER7 Δ mt. Forward
Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID.
Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a γ-retroviral.
Schematic of the PCR assay.
Polyclonal long-term repopulating stem cell clones in a primate model
Volume 26, Issue 1, Pages (January 2018)
Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation by George E. Georges, Rainer Storb, Jennifer.
Transduction of Primitive Human Marrow and Cord Blood-Derived Hematopoietic Progenitor Cells With Adeno-Associated Virus Vectors by Saswati Chatterjee,
Volume 9, Issue 4, Pages (October 2011)
Correction of a mouse model of sickle cell disease: lentiviral/antisickling β-globin gene transduction of unmobilized, purified hematopoietic stem cells.
Volume 23, Issue 9, Pages (May 2018)
by Hyung-Gyoon Kim, Kyoko Kojima, C. Scott Swindle, Claudiu V
Therapeutic levels of fetal hemoglobin in erythroid progeny of β-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer by Andrew Wilber,
Volume 25, Issue 3, Pages (March 2017)
Volume 17, Issue 9, Pages (September 2009)
Volume 23, Issue 9, Pages (May 2018)
Volume 12, Issue 6, Pages (December 2005)
Neeltje A Kootstra, Ryusuke Matsumura, Inder M Verma  Molecular Therapy 
Volume 20, Issue 5, Pages (May 2012)
Lentiviral-mediated RNAi inhibition of Sbds in murine hematopoietic progenitors impairs their hematopoietic potential by Amy S. Rawls, Alyssa D. Gregory,
Volume 4, Issue 1, Pages (January 2015)
Volume 23, Issue 5, Pages (May 2015)
Volume 10, Issue 1, Pages (July 2004)
Volume 28, Issue 2, Pages (August 2015)
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)‏ by Michaela Scherr, Anuhar Chaturvedi, Karin.
Volume 2, Issue 4, Pages (April 2008)
Volume 12, Issue 3, Pages (September 2005)
Volume 20, Issue 5, Pages (May 2012)
Araksya Izmiryan, Olivier Danos, Alain Hovnanian 
Volume 25, Issue 8, Pages (August 2017)
Kenichi Miharada, Valgardur Sigurdsson, Stefan Karlsson  Cell Reports 
HoxB4 Confers Definitive Lymphoid-Myeloid Engraftment Potential on Embryonic Stem Cell and Yolk Sac Hematopoietic Progenitors  Michael Kyba, Rita C.R.
Lentiviral vectors containing mouse Csf1r control elements direct macrophage-restricted expression in multiple species of birds and mammals  Clare Pridans,
Volume 20, Issue 10, Pages (October 2012)
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9- mediated Genome Editing  Astrid Glaser, Bradley McColl, Jim Vadolas  Molecular.
Effective Gene Therapy of Mice with Congenital Erythropoietic Porphyria Is Facilitated by a Survival Advantage of Corrected Erythroid Cells  Elodie Robert-Richard,
Volume 23, Issue 1, Pages (January 2015)
Molecular Therapy - Methods & Clinical Development
Volume 5, Issue 5, Pages (November 2015)
Volume 4, Issue 2, Pages (February 2009)
Volume 12, Issue 5, Pages (November 2005)
Volume 6, Issue 5, Pages (November 2002)
Volume 8, Issue 6, Pages (December 2003)
Volume 15, Issue 8, Pages (August 2007)
Volume 15, Issue 4, Pages (April 2007)
Volume 11, Issue 6, Pages (June 2005)
Volume 18, Issue 4, Pages (April 2010)
Volume 7, Issue 2, Pages (August 2010)
Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii. Tagging of the endogenous Py03652 gene with the gfp gene in Plasmodium yoelii.
Molecular Therapy - Nucleic Acids
Volume 9, Issue 2, Pages (February 2004)
Tobias Maetzig, Jens Ruschmann, Lea Sanchez Milde, Courteney K
Molecular Therapy - Methods & Clinical Development
Molecular Therapy - Nucleic Acids
Volume 19, Issue 1, Pages (January 2011)
Volume 18, Issue 9, Pages (September 2011)
Barcoding of Macaque Hematopoietic Stem and Progenitor Cells: A Robust Platform to Assess Vector Genotoxicity  Idalia M. Yabe, Lauren L. Truitt, Diego.
Volume 9, Issue 5, Pages (May 2004)
Volume 7, Issue 3, Pages (March 2003)
Volume 18, Issue 5, Pages (May 2016)
Volume 20, Issue 11, Pages (November 2012)
A Double-Switch Vector System Positively Regulates Transgene Expression by Endogenous microRNA Expression (miR-ON Vector)  Mario Amendola, Alice Giustacchini,
Volume 17, Issue 2, Pages (February 2009)
Presentation transcript:

Nina M. Muñoz Kiem lab May 18th, 2009 A Color Change Reporter System For I-SceI-mediated Genome Editing In Canine Hematopoietic Stem Cells Nina M. Muñoz Kiem lab May 18th, 2009

GFP Targeting Strategy. Gene Correction With A Two-IDLV System Gene Target GGGATCCAC TAGGGATAACAGGGTAAT CGGTC GCCACC ATG GTG TGA TAG GGC GAG GAG I-SceI 2 stop codons 5’ LTR RRE cPPT SFFV MGMTP140K hPGK GFP’ WPRE 3’ LTR Repair Template 5’ LTR RRE cPPT hPGK WPRE 3’ LTR Stop codon (14 a.a.) GGGATCCAC CGGTC GCCACC ATG GTG AGC AAG GGC GAG GAG 14-GFP GTC CTG CTG GAG TTC GTG TAA TGT ACA AGT AA I-SceI HA tag 5’ LTR RRE cPPT SFFV I-SceI WPRE 3’ LTR

Analysis of Gene Correction in GFP’-expressing D17 Cells. 200 400 600 800 1000 10 1 2 3 4 SSC-H GFP 8.3e-3 1.44 2.44 3.75 0l 25l 50l 100l The repair template and I-SceI were delivered into D17 cells stably expressing the GFP’ target using the two IDLVs. The volume of each IDLV used is indicated above each graph.

The expression of I-SceI (by HA Tag) and GFP was followed over time. GFP and I-SceI Expression in D17-GFP’ Cells treated with The Two-IDLV System GFP I-SceI D17 cells stably expressing the GFP’ target were transduced with the two IDLVs. The expression of I-SceI (by HA Tag) and GFP was followed over time.

Sequencing Analysis of Gene Correction in D17-GFP’ Cells 200 400 600 800 1000 10 1 2 3 4 SSC-H GFP 1.45 200 400 600 800 1000 10 1 2 3 4 SSC-H GFP 91.8 FACS sort PCR amplification of the gene target Reverse primer Target-specific! hPGK GFP’ Forward primer Gene target 14-GFP Repair template Sequence analysis 73 clones sequenced 41% corrected target 59% original target Original target Clone 1 (+1bp, NHEJ) Clone 2 (corrected) Clone 3 (original) Clone 4 (original) Clone 5 (corrected) Clone 6 (original) I-SceI site Stop codons

Transduction of Primary CD34+ Cells with The Gene Target CFU counts CFU PCR analysis MGMT intracellular staining on liquid cultures 14d after transduction 200 400 600 800 1000 10 1 2 3 4 SSC-H MGMT-PE 0.49 2.8 3.4 7.1 Mock MOI=0.5 MOI=1 MOI=10

Canine Secondary Transplant for I-SceI-mediated Gene Correction I. Collect and transduce CD34+ cells with lentiviral vector encoding target gene containing I-SceI restriction site and MGMTP140K II. Infuse cells after conditioning by irradiation Donor DLA identical recipient V. Infuse cells after myeloablative conditioning III. Treat iteratively with O6BG and BCNU IV. Collect CD34+ cells and transduce with IDLVs encoding I-SceI and repair template

Canine Secondary Transplant for ISceI-mediated Gene Conversion: Initial Observations Dog H084 was transplanted on 4/16/09 CD34+ cells product of apheresis from HLA-identical sibling (H089) were exposed twice (O/N+7h) to the lentiviral vector encoding the target gene (MOI=10). H084 received 3.7x106 cells/kg. After 3 weeks, VNTR analysis showed full chimerism (100% donor cells in peripheral blood). PCR analysis on transduced CD34+ cells plated for CFUs before infusion demonstrated 6.8% transduced cells.

Future Experiments Assess marking levels by TaqMan and MGMT intracellular staining on peripheral blood and bone marrow cells. Initiate O6BG/BCNU treatments, once platelets levels are stable, in order to increase marking levels (if any). Evaluate gene conversion in vitro using CD34+ cells from dog H084 and the two-IDLV system.